EpiPen Controversy

Mylan NV (NASDAQ: MYL)'s EpiPen controversy, in which the company may have been unjustified in raising the cost of its life saving device over the years, is far from over. Even though Mylan's CEO Heather Bresch sat in front of a U.S. House Oversight panel this week to defend the company's business...